BriaCell advanced Bria-IMT pivotal Phase 3 enrollment past 230 patients toward planned interim analysis, reporting a net loss of $35,325,292 for year ended July 31, 2026; working capital was $14,063,292 and it intends to raise additional capital.

Net loss $34.9M Diluted EPS -$6.97

Read from the MD&A section

Oct 28

Filing SEDAR+

Participation fee form

Oct 28

Filing SEDAR+

52-109F1 - Certification of annual filings - CFO (E)

All documents

Technicals

trend & momentum for long-term holders illustrative — not investment advice

Price context

position in its 52-week range

Range low 3.8000 CAD Now 5.5700 CAD · 13% Range high 17.6300 CAD

vs 200-day avg +6% vs 50-day avg +7% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

Raw-price comparisons begin at the captured split on Aug 25, 2025; windows that need an earlier baseline remain unavailable.

	5D	20D	120D	MTD	YTD
XTSE:BCT	+29.5%	+0.2%	+34.9%	+29.5%	-43.2%

Exchange listing

Market: XTSE
Ticker: BCT
ISIN: —
Security: Ordinary share
Trading currency: CAD

Company with tickers: BCTX, BCTXL, BCTXZ

Company

Website: https://briacell.com/
Investor relations: https://investors.briacell.com/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Latest price

Plus & Pro

Follow BCT during the session: the latest price, the day's change, range and volume. Closing prices stay free.

View plans Sign in

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

Earnings call · Q4 2022 2022-10-28

BriaCell Therapeutics Corp. Q4 FY2022 Earnings Call

BCT · BriaCell Therapeutics Corp.

Price & Indicators

Latest documents